Talis Biomedical Corporation Class Action Lawsuit - TLIS

According to the lawsuit, documents that the Company issued in connection with its IPO failed to disclose to investors: (1) that the comparator assay in the primary study lacked sufficient sensitivity to support Talis’s Emergency Use Authorization application for Talis One COVID-19 test; (2) that, as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (3) that, as a result, the Company’s commercialization timeline would be significantly delayed; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

In order to be eligible to join the TLIS class action lawsuit, you must have incurred a loss on shares of Talis purchased during the class period listed above.

If you suffered a loss in Talis during the relevant time frame, you have until March 8, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky, LLP announces that a TLIS class action lawsuit has been filed on behalf of investors who purchased Talis Biomedical Corporation (TLIS) common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s February 2021 initial public offering. For more on the TLIS Lawsuit please contact us today. According to the Talis Biomedical Corporation lawsuit, documents that the Company issued in connection with its initial public offering failed to disclose to investors: (1) that the comparator assay in the primary study lacked sufficient sensitivity to support Talis’s Emergency Use Authorization application for Talis One COVID-19 test; (2) that, as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (3) that, as a result, the Company’s commercialization timeline would be significantly delayed; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you suffered a loss in Talis Biomedical Corporation you have until March 8, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.